 Indegene Ltd consolidated Q2FY26 net profit at Rs. 102.1 crores
Indegene Ltd consolidated Q2FY26 net profit at Rs. 102.1 crores Dr Agarwals Health Care Ltd reports Rs. 29.69 crores consolidated PAT in Q2 FY2026
Dr Agarwals Health Care Ltd reports Rs. 29.69 crores consolidated PAT in Q2 FY2026 IIRM Holdings India Ltd consolidated Q2FY26 profit at Rs. 5.24 crores
IIRM Holdings India Ltd consolidated Q2FY26 profit at Rs. 5.24 crores Automotive Axles Ltd Q2 FY2026 net profit at Rs. 35.95 crores
Automotive Axles Ltd Q2 FY2026 net profit at Rs. 35.95 crores Lodha Developers Ltd consolidated net profit for Q2FY26 increases to Rs. 788.7 crores
Lodha Developers Ltd consolidated net profit for Q2FY26 increases to Rs. 788.7 crores 
              Mr. Amit Chandra, Institutional Research Analyst, HDFC Securities and Mr. Mohit Motwani, Institutional Research Analyst, HDFC Securities
CDSL delivered a strong revenue performance (+19.7% QoQ), driven by transaction and online data charges (KYC) revenue. Key attributes that underscore our positive stance include (1) strong momentum in transaction revenue (+178% in FY21), driven by retail activity (online brokers) and pledge income; (2) continued gain in BO account market share (+770bps YoY to 60.7%); (3) sustained growth in annual issuer charges (annuity income), led by BO accounts addition and unlisted opportunity; (4) investment in technology for enhanced security; (5) high cash generation (OCF/EBITDA of 90%) and high net cash of INR 9.1bn (11% of MCap); and (6) +18/20% revenue/EBITDA CAGR over FY21-23E, following a strong FY21. Operating margin contracted 220bps QoQ to 59.9% (stood lower than the estimate) due to wage hike and higher investments in technology (cybersecurity). We increase our revenue estimates for FY22/23 by 10.9/12.8% and raise the target multiple to 35x (from 33x earlier). FY22/23E EPS increases by 8.5/10.1%. We value CDSL on an SoTP basis by assigning 35x to FY23E core profit and adding net cash to arrive at a target price of INR 870. The stock trades at a P/E of 34.1/29.3x FY22/23E EPS. Maintain BUY.
4QFY21 highlights: CDSL revenue stood at INR 1.03bn (+19.7/+72.1% QoQ/YoY), higher than our estimate of INR 0.92bn. Annual Issuer/Transaction/IPO/KYC revenue was up +1.8/+19.8/+87.6/+52.9% QoQ. Revenue from others was down 19.1% QoQ due to lower e-voting and e- CAS revenue. Other income declined 58% QoQ due to M2M losses. On the cost front, Employee/Technology/Other cost was up 20.4/15.2/42.8%, leading to EBITDA margin contraction of 353bps QoQ. The other expenses were higher due to greater provisions and an increase in SMS cost due to Pledge authentication.
Outlook: We expect revenue growth of +21.6/+15.4 and an EBITDA margin of 63.6/64.4% in FY22/23E. The revenue CAGR of 18% over FY21-23E assumes +18/18/27/27% revenue CAGR in Issuer/Transaction/ IPO/KYC revenue. Core PAT CAGR over FY21-23E is at +22%.